PF-03446962

DRUG5 trials

Sponsors

Pfizer, NCIC Clinical Trials Group, Duke University

Conditions

Advanced Solid TumorsCarcinoma, HepatocellularColorectal CancerMalignant Pleural MesotheliomaNeoplasms

Phase 1

A First In Patient, Study Of Investigational Drug PF-03446962 In Patients With Advanced Solid Tumors

CompletedNCT00557856

PfizerAdvanced Solid Tumors

Start: 2007-11-30End: 2013-03-31Updated: 2015-10-19

Asian Phase I Study Of PF-03446962

CompletedNCT01337050

PfizerNeoplasms

Start: 2011-07-31End: 2014-03-31Updated: 2015-10-28

Safety Study of Regorafenib With PF-03446962 to Treat Colorectal Cancer

CompletedNCT02116894

Duke UniversityColorectal Cancer

Start: 2014-08-31End: 2016-05-31Updated: 2019-03-14

Phase 2

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

CompletedNCT01486368

NCIC Clinical Trials GroupMalignant Pleural Mesothelioma

Start: 2012-06-26End: 2015-02-13Updated: 2023-08-04

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

TerminatedNCT01911273

PfizerCarcinoma, Hepatocellular

Start: 2013-10-31End: 2014-07-31Updated: 2015-10-28

Related Papers

Phase I study of PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1, in patients with hepatocellular carcinoma.

2016-06-2031 citations

Phase Ib study of regorafenib (rego) and PF-03446962 (PF) in patients with refractory metastatic colorectal cancer (mCRC) (REGAL).

Journal of Clinical Oncology2016-05-202 citations

Phase 1 study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC): Correlation of tumor and serum biomarker data with disease control.

Journal of Clinical Oncology2014-05-202 citations